A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs that are designed specifically to treat genetic or familial DCM.
The purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM).
The main goals of the study are:
* To assess the effect of danicamtiv on cardiac function using echocardiogram.
* To evaluate the impact of danicamtiv on exercise capacity
* To evaluate the safety and tolerability of danicamtiv
Participants will:
* Take danicamtiv or placebo every day for approximately 6 months
* Visit the clinic about 12 times for initial evaluation, checkups, tests and follow up

开始日期2026-02-13

申办/合作机构

Kardigan, Inc.

NCT06027437

/ Completed临床1期

A Phase 1, Open-label, Randomized, Single-dose, 3-Period, 3-Sequence Crossover Study to Assess the Relative Bioavailability of the Intended Commercial Formulation Versus the Previous MyoKardia Formulation of Danicamtiv and to Assess the Effect of Food on the Pharmacokinetics of the Intended Commercial Formulation in Healthy Adult Participants

The purpose of this study is to assess the relative biological availability and the effect of food on the drug levels of Danicamtiv in health adults.

开始日期2023-09-05

申办/合作机构

Bristol Myers Squibb Co.

NCT05952089

/ Completed临床1期

An Open-label, Single-sequence Study to Evaluate the Effect of Coadministration of Danicamtiv on the Pharmacokinetics of Midazolam in Patients With Stable Heart Failure With Reduced Ejection Fraction

The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).

开始日期2023-08-17

申办/合作机构

Bristol Myers Squibb Co.

100 项与 Danicamtiv 相关的临床结果

登录后查看更多信息

100 项与 Danicamtiv 相关的转化医学

登录后查看更多信息

100 项与 Danicamtiv 相关的专利（医药）

登录后查看更多信息

项与 Danicamtiv 相关的文献（医药）

2025-12-01·JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy

Article

作者: Maruyama, Sonomi ; Halliday, Brian P ; Solomon, Scott ; Cunningham, Jonathan W ; Garcia-Pavia, Pablo ; Pereira, Naveen L ; Maya, Juan ; Kurio, Gregory ; Anto, Anu R ; Gerull, Brenda ; Ginns, Jonathan ; Rodriguez, Hector M ; Edelberg, Jay M ; Lakdawala, Neal K ; Elliott, Perry Mark ; Meder, Benjamin ; Hershberger, Ray E ; Barriales-Villa, Roberto ; Januzzi, James L ; Anderson, Robert L ; Jarugula, Praneeth ; Papadaki, Maria ; Mohran, Saffie E ; Gimeno, Juan R ; Li, Wanying ; Adler, Eric ; Del Rio, Carlos L

BACKGROUND:

Precision therapies for dilated cardiomyopathy (DCM) are lacking despite diverse manifestations and clinical trajectories based on underlying etiology. DCM-associated pathogenic variants in cardiac beta-myosin heavy chain (MYH7) and titin (TTN) can impair the function/availability of cardiac myosin. Danicamtiv is a novel investigational small molecule that selectively enhances cardiac myosin function.

OBJECTIVES:

The study sought to translationally evaluate danicamtiv in the setting of myosin dysfunction, from in vitro assessments to a clinical trial exploring its safety and efficacy in DCM due to MYH7 or TTN variants, or other causes (either positive or negative genetic results).

METHODS:

The danicamtiv effects on DCM-variant cardiac myosin enzyme activity and skinned left ventricular (LV) fiber force generation were assessed in vitro. A phase 2a, baseline-controlled, open-label trial enrolled individuals with DCM into cohorts by variants (MYH7 or TTN) or other causes. In the week of treatment period (TP)1, participants received oral danicamtiv 25 mg twice daily with dose adjustment in TP2 to 10 or 50 mg twice daily. The primary endpoint was safety/tolerability; secondary endpoints included echocardiography-assessed changes in cardiac structure/function.

RESULTS:

In vitro, danicamtiv increased the activity of wild-type and DCM myosin, increasing force production in cardiac fibers. Forty-one participants were enrolled in the trial (mean age 49.6 ± 13 years; mean baseline LV ejection fraction 33.4% ± 8.0%). Twelve had MYH7 variants, 14 had TTN variants, and 15 had other cause DCM. Treatment-emergent adverse events were reported in 22 (53.7%) of 41 participants (all mild or moderate; 1 discontinuation); an asymptomatic increase in cardiac troponin was detected in 3 participants in the other causes cohort. After TP2, the MYH7 and TTN cohorts showed improvements from baseline in LV ejection fraction (MYH7: 8.8% [95% CI: 5.03%-12.64%]; TTN: 5.9% [95% CI: 2.59%-9.28%]) but less in the other causes cohort (4.4% [95% CI: -0.90% to 9.73%]).

CONCLUSIONS:

Selective in vitro enhancement of cardiac myosin motor function and myofilament force generation by danicamtiv prompted clinical evaluation. A short course of danicamtiv was generally well tolerated in participants with DCM. Echocardiography outcomes were consistent with a danicamtiv-induced enhancement of myosin function/availability; MYH7 and TTN cohorts generally had the most favorable responses in contractile function. (Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy Due to Genetic Variants or Other Causalities; NCT04572893).

2025-10-01·JOURNAL OF PHYSIOLOGY-LONDON

Danicamtiv increases cardiac mechanical efficiency

Article

作者: Taberner, Andrew J. ; Han, June‐Chiew ; Tran, Kenneth ; Meehan, Trent ; Pham, Toan

Abstract:

Danicamtiv is a recently developed cardiac‐specific myosin activator that directly increases actomyosin interaction and, thereby, increases force. It is currently studied pre‐clinically and has entered clinical trials. In this study, we provide the first assessment of its effects on cardiac energetics. Ventricular trabeculae from rats were isolated and studied in vitro. Each trabecula was stimulated to produce twitch force over ranges of muscle lengths and afterloads, with muscle heat output simultaneously measured. Each trabecula was superfused with and without danicamtiv (5 µM). In both interventions, muscles were required to undergo both isometric and work‐loop contraction protocols to quantify the components of heat output – that from muscle contraction, that from intracellular Ca2+ cycling and that from actomyosin cross‐bridge cycling. Danicamtiv was found to increase twitch force, muscle heat and cross‐bridge heat, with no effect on the energy expenditure associated with intracellular Ca2+ cycling. Danicamtiv slowed isometric twitch force kinetics and slowed shortening kinetics. Danicamtiv increased the extent of muscle shortening, increased muscle work output and increased mechanical efficiency, while preserving cross‐bridge efficiency. In conclusion, danicamtiv increases mechanical efficiency, the mechanism of which arises from the greater increase of force and muscle shortening that increase mechanical work than the increase of heat. The relative smaller increase of heat is due to a null effect of danicamtiv on the energy for intracellular Ca2+ cycling. Our results provide perspective for the utility of danicamtiv as an inotropic agent not only for mechanical enhancement but also for energetic enhancement in increasing mechanical efficiency. image

Key points:

Clinical trials are presently exploring the potential of a new myotrope, danicamtiv, to improve cardiac mechanics by increasing muscle force output.A range of active pre‐clinical research is likewise uncovering the biophysical mechanism of how danicamtiv affects cardiac mechanics, increases cardiac force and slows contractile kinetics.This study provides the first energetic assessment of danicamtiv by measuring muscle heat output, and shows that danicamtiv increases cardiac energy efficiency. The mechanism of the increased efficiency resides in the increase of muscle force–length work greater than the increase of muscle heat.This study demonstrates that danicamtiv is a cardiac myotrope that not only enhances mechanics, but also exerts its enhancement effect on energetics.

2025-08-26·PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Danicamtiv reduces myosin’s working stroke but activates the thin filament by accelerating actomyosin attachment

Article

作者: Greenberg, Lina ; Squarci, Caterina ; Scott, Brent ; Campbell, Kenneth S. ; Greenberg, Michael J.

Heart failure is a leading cause of death worldwide, and even with current treatments, the 5-y transplant-free survival rate is only ~50 to 70%. As such, there is a need to develop new treatments for patients that improve survival and quality of life. Recently, there have been efforts to develop small molecules for heart failure that directly target components of the sarcomere, including cardiac myosin. Danicamtiv is one of these molecules; however, its direct effects on myosin’s single molecule mechanics and kinetics are not well understood. Using optical trapping techniques, stopped flow transient kinetics, and in vitro reconstitution assays, we found that danicamtiv reduces the size of cardiac myosin’s working stroke without affecting actomyosin detachment kinetics at the level of individual crossbridges. We demonstrate that danicamtiv accelerates actomyosin association kinetics, leading to increased recruitment of myosin crossbridges and subsequent thin filament activation at physiologically relevant calcium concentrations. We demonstrate important mechanistic differences with another cardiac myosin binding myotrope, omecamtiv mecarbil. Finally, we computationally model how the observed changes in mechanics and kinetics at the level of single crossbridges can contribute to increased cardiac contraction. Taken together, our results have important implications for the design of sarcomeric-targeting compounds for heart failure.

项与 Danicamtiv 相关的新闻（医药）

2026-03-30

·FierceBiotech

Kardigan hypertension drug tangles biomarker win with blood pressure miss in phase 2 trial

Patients with the highest hypertensive burden—defined as baseline oSBP of over 150 mmHg—experienced the greatest reduction, Kardigan noted. \n Kardigan’s tonlamarsen reduced a key biomarker for hypertension in a phase 2 trial, but missed the study’s other goal of significantly reducing blood pressure.The biotech evaluated monthly 90 mg doses of the antisense oligonucleotide, which is licensed from Ionis Pharmaceuticals, in the mid-stage Kardinal study of 198 patients with uncontrolled hypertension. Tonlamarsen is designed to target angiotensinogen (AGT) in order to regulate the renin-angiotensin‑aldosterone system, a hormone system that controls blood pressure.The trial demonstrated a statistically significant reduction in levels of AGT, hitting one of the trial’s primary endpoints. Specifically, AGT had fallen 67% by Week 20 for patients who received five monthly doses of tonlamarsen compared to a 23% reduction among those who received a single dose followed by placebo.However, the company was unable to demonstrate a statistically significant difference between the in-office systolic blood pressure (oSBP) of the two cohorts at the same time-point, missing the study’s co-primary endpoint. Kardigan blamed this miss on an “unexpected, prolonged reduction in blood pressure in the single-dose arm.”Kardigan explained that both treatment groups had seen a “clinically meaningful” reduction in oSBP compared to baseline. The single-dose cohort saw oSBP fall from 9.8 mmHg to 3.5 mmHg, while the five-dose group saw a fall from 9.8 mmHg to 3.6 mmHg.Patients with the highest hypertensive burden—defined as baseline oSBP of over 150 mmHg—experienced the greatest reduction, Kardigan noted. The company used this data to justify its plans to launch a phase 2b study in patients with acute severe hypertension post-hospitalization later this year. Meanwhile, participants in the five-dose cohort experienced a decline in surges of at-home systolic blood pressure (hSBP) above 150 mmHg over the course of the study relative to baseline. “The Kardinal clinical trial supported tonlamarsen’s hypothesized mechanism of action by demonstrating sufficient modulation of angiotensinogen, resulting in clinically meaningful blood pressure lowering, and potential for a favorable safety profile, particularly in patients with higher hypertensive burden,” the biotech’s co-founder and Chief Medical Officer Jay Edelberg, M.D., Ph.D., said in the March 28 release.“Together, these findings strengthen our therapeutic hypothesis for tonlamarsen in patients with acute severe hypertension and will inform the Kardinal-ASH phase 2b clinical trial in this high-risk population with an urgent unmet medical need,” Edelberg added.In addition to plans to launch a phase 2b study of tonlamarsen, Kardigan also has two other cardio drugs in late-stage development. They include danicamtiv, a phase 2b/3-stage cardiac myosin activator licensed from Bristol Myers Squibb and originally discovered by MyoKardia.Kardigan launched last year with $300 million in funding, founded by a team of former MyoKardia execs, including co-founder, CEO and chair Tassos Gianakakos, who previously led MyoKardia for seven years.Since then, Kardigan scored a $254 million series B, which it has used to fund development of tonlamarsen and danicamtiv as well as ataciguat, a guanylate cyclase activator from Sanofi and the Mayo Clinic that Kardigan is pursuing for calcific aortic valve stenosis.Gianakakos told Fierce earlier this year that Kardigan plans to market and commercialize its potential products itself. The Bay Area biotech also has a phase 2 program that is currently under wraps.

临床2期临床结果寡核苷酸

2026-03-30

·BioSpace

Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC

Patients treated with tonlamarsen experienced statistically significant reductions in plasma angiotensinogen levels and clinically meaningful changes in systolic blood pressure Results support initiation of Phase 2b clinical trial of tonlamarsen in patients with acute severe hypertension SOUTH SAN FRANCISCO, Calif., & PRINCETON, N.J.--(BUSINESS WIRE)-- #ACC26 -- Kardigan™ , a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced results from KARDINAL, a Phase 2 clinical trial evaluating the effects of tonlamarsen in patients with uncontrolled hypertension despite treatment with two or more antihypertensive medications. Data were presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.26) and simultaneously published in The Journal of the American College of Cardiology (JACC) . In the clinical trial, tonlamarsen, an investigational antisense oligonucleotide (ASO) targeting angiotensinogen (AGT), demonstrated a statistically significant reduction in plasma AGT levels and a clinically meaningful reduction in in-office systolic blood pressure (oSBP) from baseline to Week 20. These results highlight the intended biological effect of tonlamarsen and support evaluation in Kardigan’s planned Phase 2b clinical trial in patients with acute severe hypertension (ASH) post-hospitalization. After a four-week placebo run‑in period, all eligible subjects received a single 90 mg tonlamarsen injection for a four-week active run-in period and were then randomized to continued monthly dosing of tonlamarsen or placebo for 16 weeks. The results of the clinical trial demonstrated a dose‑dependent, statistically significant reduction in AGT levels, with patients receiving five monthly doses of 90 mg tonlamarsen achieving a 67% mean reduction from baseline to Week 20 compared with a 23% mean reduction in patients receiving a single dose (p150 mmHg at baseline) in the five-dose tonlamarsen group experienced the greatest reductions in oSBP (-8.9 mmHg at Week 20), supporting the clinical rationale for evaluating tonlamarsen in patients with ASH. An additional post hoc analysis showed that participants who received five doses of tonlamarsen experienced a decline in surges of at-home systolic blood pressure (hSBP) above 150 mmHg over the course of the study relative to baseline at Week 0. Furthermore, an absolute 28% reduction in such surges was observed for the five-dose tonlamarsen arm at Week 20 compared to those who received a single dose (50%; 95% CI: 34.9-65.1 versus 78%; 95% CI: 64.0 to 88.5). Tonlamarsen was generally well-tolerated, with a safety pro to prior studies. Worsening renal function was uncommon and there were no meaningful signs of treatment-related hypotension or hyperkalemia. “The KARDINAL clinical trial supported tonlamarsen’s hypothesized mechanism of action by demonstrating sufficient modulation of angiotensinogen, resulting in clinically meaningful blood pressure lowering, and potential for a favorable safety profile, particularly in patients with higher hypertensive burden,” said Jay Edelberg, M.D., Ph.D., co-founder and chief medical officer at Kardigan. “Together, these findings strengthen our therapeutic hypothesis for tonlamarsen in patients with acute severe hypertension and will inform the KARDINAL-ASH Phase 2b clinical trial in this high-risk population with an urgent unmet medical need.” KARDINAL was a randomized, double-blind, placebo-controlled, parallel group, Phase 2 clinical trial for the management of chronic hypertension in 198 patients with uncontrolled hypertension (systolic blood pressure greater than 135 mmHg and less than or equal to 170 mmHg) on a background of two to five therapies for the chronic management of hypertension, including greater than 80% on angiotensin-converting enzyme (ACE) or angiotensin receptor blocker (ARB) therapy. The clinical trial was designed to assess the safety and efficacy of tonlamarsen, including the use of the Prolaio™ technology platform for home-based, high-density blood pressure and ECG data collection to support the objective assessment of blood pressure management and heart failure parameters. The baseline mean oSBP of participants was 147.6 mmHg and 145.9 mmHg for the single dose and five-dose tonlamarsen arms respectively. “While continued dosing with tonlamarsen reduced angiotensinogen more than a one-time treatment, both treatment strategies reduced blood pressure to a similar extent,” said Luke Laffin, M.D., principal investigator and co-director of the Center for Blood Pressure Disorders in the Heart, Vascular & Thoracic Institute at Cleveland Clinic. “It’s important to continue to study tonlamarsen in patients who really need it, including those with acute severe hypertension, since so many struggle to take daily medications.” Tonlamarsen is one of three late-stage investigational candidates that Kardigan is developing in parallel, as part of its portfolio of targeted product candidates designed to modify the underlying cause of various cardiovascular diseases. The company intends to start the tonlamarsen randomized Phase 2b clinical trial in ASH later this year. The company is also developing danicamtiv i , an investigational cardiac myosin activator targeting familial and genetic dilated cardiomyopathy (DCM) driven by sarcomeric mutations to restore cardiac function through direct activation in both the left atrium and left ventricle, and ataciguat ii , a once-daily, investigational oral soluble guanylate cyclase (sGC) activator, as a potential first-in-class treatment for moderate calcific aortic valve stenosis and an alternative to “watchful waiting.” About Acute Severe Hypertension (ASH) Acute severe hypertension (ASH) is a sudden elevation in blood pressure greater than or equal to 180/110 mmHg. Approximately six million patients present in emergency rooms with ASH and about two million cases lead to hospitalization each year in the United States. Following hospital discharge, patients with ASH are in a high-risk, vulnerable period, and often experience ongoing health challenges in the weeks and months after hospitalization, with persistent hypertension and continued risk of acute end-organ damage. ASH, often triggered by stress-hormones, is associated with dysregulation of angiotensinogen (AGT), a key upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), the main pathway in blood pressure regulation. While many people who develop ASH have underlying chronic resistant or uncontrolled hypertension, the near-term risk associated with this acute event is underappreciated and has rarely been studied as a separate condition. There are currently no treatments indicated for the post-hospitalization management of blood pressure in patients with ASH. About Tonlamarsen Tonlamarsen is an investigational, subcutaneous, once-monthly, liver-directed antisense oligonucleotide (ASO) designed for the management of blood pressure in patients with acute severe hypertension (ASH) post-hospitalization. Tonlamarsen targets hepatic angiotensinogen (AGT), the sole precursor of the Renin-Angiotensin‑Aldosterone System (RAAS), which regulates blood pressure, vascular tone, and blood volume. By directly down‑modulating AGT at its source in the liver, tonlamarsen is designed to modulate the RAAS pathway upstream as an alternative approach to improving blood pressure management. Kardigan in-licensed exclusive worldwide development and commercialization rights to tonlamarsen, an investigational drug discovered and developed by Ionis Pharmaceuticals. About Kardigan Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Led by a proven and experienced management team, Kardigan is reimagining cardiovascular drug discovery and development through an integrated approach that unites deep cardiovascular biology, real-world patient data, and advanced analytics to enable more precise, efficient, and informed development of novel therapies. The company is based in South San Francisco, California, and Princeton, New Jersey. To learn more, visit Kardigan.bio . i Kardigan in-licensed exclusive worldwide development and commercialization rights to danicamtiv, an investigational drug discovered at MyoKardia and further developed by Bristol Myers Squibb. ii Kardigan acquired rights to ataciguat, an investigational drug developed by, and in-licensed from, Sanofi and Mayo Clinic. Contacts Media Michael Bachner Executive Director, Corporate Communications +1 (609) 664-7308 mbachner@kardigan.bio Investors investors@kardigan.bio

临床结果临床2期引进/卖出

2026-03-11

·百度百家

2025生物医药融资榜：AI+心血管代谢双轮驱动

2025年，全球生物医药私募融资数量同比下降约18%，却创下近五年单笔最大规模纪录——前十笔交易合计吸金近40亿美元。赛道热度明显向AI药物设计、心血管代谢、神经科学三大前沿集中，传统肿瘤小分子赛道遇冷。以下企业按融资金额降序排列，带您速读2025年最吸睛的十笔Biotech交易。 2.1 ◇ Isomorphic Labs：6亿美元登顶，AI造药第一股轮次：未披露日期：3月投资方：Thrive Capital、GV、Alphabet Isomorphic 2021年才成立，却凭AlphaFold 3模型快速跻身“现金王”。2024年1月，公司与礼来、诺华分别签订总价值40亿美元战略合作，直接把AI药物设计推向C位。联合创始人Demis Hassabis与John Jumper更因模型贡献摘得2024年诺贝尔化学奖，让“算法造药”故事再添权威注脚。 2.2 ◇ Kailera Therapeutics：B轮再融6亿美元，GLP-1管线加速轮次：B轮日期：10月投资方：Bain Capital Private Equity、Atlas Venture、Bain Capital Life Sciences等 2024年估值4亿美元的Kailera，2025年以6亿美元B轮刷新纪录。公司手握瑞普泊肽（KAI-9531）——全球首个每周一次口服GLP-1候选药，正在开展III期临床；同时手握恒瑞医药引进的4款GLP-1类化合物独家海外权利，“研发+商业化”双引擎已就位。 2.3 ◇ Verdiva Bio：4.1亿美元A轮，口服GLP-1“周给”概念第一股轮次：A轮日期：1月投资方：Forbion、General Atlantic、RA Capital Management等把“每日打针”变成“每周一片”，Verdiva Bio的伊诺格鲁肽片全球在研口服GLP-1唯一做到每周给药，差异化优势明显。公司已预留现金等待收购更多资产，“口服+周给”赛道或迎新整合者。来源：丁香园 Insight 数据库 2.4 ◇ Tubulis：4.01亿美元C轮，ADC“难靶”突围者轮次：C轮日期：10月投资方：Venrock Healthcare Capital Partners、Wellington Management、Ascenta Capital等 Tubulis把“不可能”做成“可能”：抗NaPi2b ADC TUB-040在铂类耐药卵巢癌中总体缓解率达59%，且安全性优异。当同行纷纷逃离“难靶”领域时，Tubulis用硬数据证明“坚持+差异化靶点”也能闯出一片天。 2.5 ◇ MapLight Therapeutics：3.725亿美元D轮，精神分裂症复方口服药押注轮次：D轮日期：7月投资方：Forbion、Goldman Sachs Alternatives、Sanofi等 ML-007C-MA是公司核心资产——毒蕈碱受体激动剂+外周抗胆碱能药物固定剂量复方口服制剂，针对精神分裂症阳性症状。上市后若成功，有望成为首个改善患者依从性的口服复方精神病药。 2.6 ◇ Eikon Therapeutics：3.507亿美元D轮，TLR7/8+PARP双线推进轮次：D轮日期：2月投资方：Lux Capital、Alexandria Venture Investments、Ame Cloud Ventures等 Eikon的TLR7/8激动剂BDB-001即将在黑色素瘤与肺癌中公布中期数据；同时引进的两款PARP1抑制剂EIK1003/EIK1004也处于临床阶段。公司2025年2月D轮后，又在2026年2月IPO募资3.81亿美元，“免疫+基因修复”双管线储备充足弹药。 2.7 ◇ Lila Sciences：3.5亿美元A轮，Flagship孵化AI科学工厂轮次：A轮日期：9月投资方：Braidwell、Collective Global、Altitude Life Science Ventures等 Lila Sciences用AI指导试验设计与执行，目标是把新药开发周期缩短一半。成立仅两年便完成两轮融资，其中A轮3.5亿美元将全部投入“AI科学工厂”基础设施与人才扩张。Flagship的孵化基因+大额资本加持，让Lila成为AI药物研发赛道最受瞩目的新秀。 2.8 ◇ Kriya Therapeutics：3.2亿美元D轮，慢病赛道多管线并行轮次：D轮日期：8月投资方：Patient Square Capital、Premji Invest等 Kriya在神经系统、眼科与代谢三大慢病领域布局三款临床阶段药物。过去数月高管团队完成“换血”：前辉瑞血液学研发负责人Greg Di Russo与前Rectify Pharma CFO Sachiyo Minegishi相继加盟，为后续商业化铺路。公司自成立累计融资超9亿美元，“慢病多管线+成熟管理团队”成为其核心竞争力。来源：丁香园 Insight 数据库 2.9 ◇ Kardigan：3亿美元A轮，MyoKardia原班人马再出发轮次：A轮日期：1月投资方：Perceptive Advisors、Arch Venture Partners、Sequoia Heritage等 Kardigan在成立当年即完成收购Prolaio心血管数据平台，并锁定原MyoKardia核心研发团队。公司计划用9个月后的B轮资金继续收购后期研发资产，“数据+研发+商业化”三位一体打造心血管特药平台。遗传性心肌病候选药Danicamtiv已进入IIb/III期。 2.10 ◇ Kardigan：2.54亿美元B轮，MyoKardia“旧将”归位轮次：B轮日期：10月投资方：Fidelity Management & Research Company等距离A轮仅9个月，Kardigan再度募得2.54亿美元。公司近期通过授权方式把Danicamtiv、Tonlamarsen、Ataciguat三款后期资产收入囊中，其中Danicamtiv曾由MyoKardia开发并被BMS以130亿美元收购，如今再次回归Kardigan。Kardigan已明确表示将自主推进产品上市并负责商业化，“旧将+老药新做”有望跑出高回报率案例。

并购抗体药物偶联物临床3期引进/卖出临床2期

100 项与 Danicamtiv 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
家族性扩张型心肌病	临床3期	美国	Kardigan, Inc.	2026-02-13
家族性扩张型心肌病	临床3期	丹麦	Kardigan, Inc.	2026-02-13
家族性扩张型心肌病	临床3期	法国	Kardigan, Inc.	2026-02-13
家族性扩张型心肌病	临床3期	匈牙利	Kardigan, Inc.	2026-02-13
家族性扩张型心肌病	临床3期	意大利	Kardigan, Inc.	2026-02-13
家族性扩张型心肌病	临床3期	西班牙	Kardigan, Inc.	2026-02-13
家族性扩张型心肌病	临床3期	瑞典	Kardigan, Inc.	2026-02-13
家族性扩张型心肌病	临床3期	英国	Kardigan, Inc.	2026-02-13
扩张型心肌病	临床2期	法国	Bristol Myers Squibb Co.	2018-02-06
扩张型心肌病	临床2期	荷兰	Bristol Myers Squibb Co.	2018-02-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04572893 (Pubmed \| J Am Coll Cardiol)	临床2期	扩张型心肌病 MYH7 variants \| TTN variants	41	Danicamtiv	艱糧餘膚顧壓遞獵齋鑰(鏇窪願鹹築壓餘襯廠艱) = 鑰鹹鏇顧願顧夢顧遞遞鏇淵齋衊淵選製選衊願 (選築廠餘鑰淵壓範鑰鏇, 5.03 ~ 12.64) 更多	积极	2025-12-01
NCT04572893 (Literature \| Company_Website) 人工标引	临床2期	扩张型心肌病	41	Danicamtiv (MYH7 cohort)	壓壓築鏇製鬱構製鹽蓋(廠壓遞蓋願鏇製範觸築) = 壓鹹淵襯鏇遞獵選鹹廠觸廠齋鹽艱觸憲鏇製襯 (艱淵襯膚鹽顧糧鑰憲餘 )	积极	2025-09-29
				Danicamtiv (TTN cohort)	壓壓築鏇製鬱構製鹽蓋(廠壓遞蓋願鏇製範觸築) = 鹽鏇襯鹹顧餘艱獵獵鹹觸廠齋鹽艱觸憲鏇製襯 (艱淵襯膚鹽顧糧鑰憲餘 )
NCT03447990 (Pubmed \| Eur J Heart Fail) 人工标引	临床2期	心脏衰竭	40	Danicamtiv	觸鏇鏇構廠繭簾遞顧衊(製憲鏇壓構蓋鹽衊鏇蓋) = 糧鹹壓壓網壓鏇願蓋願選壓遞觸範淵鏇醖鹹選 (顧膚顧襯遞構構簾窪選 ) 更多	积极	2020-09-01
				Placebo	觸鏇鏇構廠繭簾遞顧衊(製憲鏇壓構蓋鹽衊鏇蓋) = 鹽鬱膚選鬱遞夢鏇遞鹽選壓遞觸範淵鏇醖鹹選 (顧膚顧襯遞構構簾窪選 )